Quick Answer
X4 Pharmaceuticals, Inc reported Operating Income Loss of -$86.88 million for the year ending 2025.
- X4 Pharmaceuticals, Inc showed a decrease of -138.7% in Operating Income Loss from 2024 to 2025.
- This data is from X4 Pharmaceuticals, Inc's annual report (Form 10-K), filed with the SEC on March 17, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 10 years of available data (2016 to 2025), X4 Pharmaceuticals, Inc's Operating Income Loss has declined by 256.9%.
- Historical annual values: Fiscal year 2025: -$86.88 million | Fiscal year 2024: -$36.40 million | Fiscal year 2023: -$107.52 million | Fiscal year 2022: -$87.57 million | Fiscal year 2021: -$85.11 million | Fiscal year 2020: -$59.87 million | Fiscal year 2019: -$51.70 million | Fiscal year 2018: -$29.09 million | Fiscal year 2017: -$22.25 million | Fiscal year 2016: -$24.35 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: